Core 1: Administrative and Communication Core

核心 1：行政和沟通核心

• 批准号: 10226186
• 负责人: Nikhil C. Munshi
• 金额: $ 22.98万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-12-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10226186
• 关键词: Address; Advisory Committees; Algorithms; Basic Science; Behavior; Cancer Center; Clinical; Clinical Research; Clinical Trials; Collaborations; Communication; Dana-Farber Cancer Institute; Disease; France; Genomic Instability; Genomics; Goals; Grant; Innovative Therapy; Institutes; International; Laboratories; Lead; Link; Massachusetts; Molecular; Molecular Abnormality; Monitor; Multiple Myeloma; Outcome; Patients; Research; Research Personnel; Research Project Grants; Resources; Science; Site; Technology; Therapeutic; Time; Tissue Banks; Translational Research; Travel; cancer genomics; collaborative trial; data exchange; epigenomics; meetings; molecular targeted therapies; next generation; novel; pre-clinical; programs; sample collection; survival outcome; targeted treatment; translational medicine

Project summary (Core 1) This proposal brings together the translational medicine and research expertise of Dana-Farber Cancer Institute (DFCI), Dana Farber/Harvard Cancer Center, and Massachusetts Institute of Technology (MIT) with the clinical research strength of Intergroupe Francophone du Myeloma (IFM) in France and the genomics expertise of the Sanger Institute in the UK to develop a curative strategy for MM. In this international collaborative renewal application, we now propose to build on our highly successful genomic, preclinical, clinical, and administrative strengths to address the next generation of questions that will ultimately lead to therapeutic advances for cure. Most importantly, our current study has confirmed that achieving MRD negative status provides significantly superior survival outcome. In this proposal, we will now undertake an international collaborative trial to address the next most important issue of how MRD status will inform our therapeutic decision algorithm (Project 1). Importantly, the large number of uniformly treated patients will allow us to both identify genomic and epigenomic correlates of disease behavior (Project 2) and identify molecular circuits and validate novel combination targeted therapeutic approaches (Project 3) as well as to define the mechanisms and clinical implications of genomic instability in MM (Project 4). This unique international collaborative effort requires significant co-ordination of effort, integration of strategies, monitoring and oversight of various functions, and communication between investigators at various dispersed sites. The key function of Core A is integration of the research efforts and communication between investigators. Scientific and administrative integration is essential to assure successful interaction between the four Projects, as well as between the laboratory and clinical components within and between projects in this multinational multi-institutional program. Therefore, this central core will provide the link between various projects and successfully co-ordinate the clinical study and the proposed correlative science. To aid in achieving these goals, Core A will: monitor the timely conduct of the clinical study and assure progress in tissue collection, processing and usage to co- ordinate interaction between the clinical and correlative science studies (Specific Aim 1); co-ordinate communication, and exchange of data between investigators at various international sites (Specific Aim 2); provide necessary resources, fiscal oversight and administrative support for projects and cores (Specific Aim 3); facilitate intra-programatic interactions, meetings, travel and Internal and External Advisory Committees (Specific Aim 4).

项目摘要(核心1) 这项建议将Dana-Farber癌症的转化医学和研究专业知识结合在一起 DFCI研究所、Dana Farber/哈佛癌症中心和麻省理工学院(MIT) 法国法语骨髓瘤集团(IFM)的临床研究实力及基因组学 英国桑格研究所的专业知识，为MM制定治疗策略。 协作续订应用程序，我们现在建议在我们非常成功的基因组、临床前 临床和管理优势，以解决最终将导致 为了治愈而取得的治疗进展。最重要的是，我们目前的研究已经证实，实现MRD阴性 状态提供显著更好的生存结果。在这项提案中，我们现在将进行一项国际 合作试验以解决下一个最重要的问题，即MRD状态将如何影响我们的治疗 决策算法(项目1)。重要的是，大量统一治疗的患者将使我们能够 确定疾病行为的基因组和表观基因组相关性(项目2)，并确定分子电路和 验证新的组合靶向治疗方法(项目3)并确定机制 以及多发性骨髓瘤基因组不稳定性的临床意义(项目4)。这一独特的国际合作努力 需要大力协调努力，整合战略，监测和监督各种 职能，以及分散在不同地点的调查人员之间的沟通。核心A的关键功能是 整合研究工作和调查人员之间的沟通。科学与行政 整合对于确保四个项目之间以及 在这一跨国多机构计划中，实验室和临床部分在项目内和项目之间。 因此，这个中央核心将提供各个项目之间的联系，并成功地协调 临床研究和提出的相关科学。为了帮助实现这些目标，核心A将：监测 及时进行临床研究，确保组织收集、加工和使用的进展，以共同 协调临床和相关科学研究之间的互动(具体目标1)；协调 不同国际地点调查员之间的沟通和数据交换(具体目标2)； 为项目和核心提供必要的资源、财政监督和行政支助(具体目标 3)；促进方案内互动、会议、旅行以及内部和外部咨询委员会 (具体目标4)。